Back to top
more

Anixa Biosciences (ANIX)

(Delayed Data from NSDQ)

$3.34 USD

3.34
37,010

+0.02 (0.60%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $3.39 +0.05 (1.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.

Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus

Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.

Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised

Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss

Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.

Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates

Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.

Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues

Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues

Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.

Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up

Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.

Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up

Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.

Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues

Apellis (APLS) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.

Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug

Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.

Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia

Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.

Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates

Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.

Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies

Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.

Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus

Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update

Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.

FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y

FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.

Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up

Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.

Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View

Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.

Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat

Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.

Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates

Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.